We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Microplastics and Nanoplastics in Human Blood: Current Evidence, Practical Measurement Limitations, and the Need for Scalable Tests for Public Health Studies and Routine Clinical Use
Summary
Scientists have found tiny plastic particles (called microplastics and nanoplastics) in human blood using several different testing methods, but this review points out that these methods don't agree with each other well enough to give us a clear, standardized picture of how much plastic is really in our bodies. This matters because without consistent, reliable testing, it's hard to know how exposure to these particles might affect our health over time, the review calls for better, more scalable tests so doctors and researchers can actually track this consistently in the future.
Microplastics (MPs) and nanoplastics (NPs) have now been reported in human blood using multiple analytical approaches, including pyrolysis–gas chromatography/mass spectrometry (Py-GC/MS), micro-Fourier transform infrared spectroscopy (µFTIR), Raman-based methods, fluorescence imaging, and Nile Red-based flow cytometry. Published studies collectively support the presence of plastic-associated material in human circulation, but they do not yet constitute a standardized blood-testing framework. Existing methods differ substantially in sample preparation, specimen volume, particle-size sensitivity, analytical output, workflow duration, and whether results are reported as polymer mass, individually characterized particles, or fluorescent events. These differences limit direct comparisons across studies and create substantial challenges for translation to longitudinal human exposure monitoring. This review examines published approaches for detecting MPs and NPs in human blood, with particular attention to their practical workflows and analytical outputs. It distinguishes instrument acquisition time from total sample-to-result time, examines limitations associated with small-volume blood sampling and dried-blood approaches, and discusses the implications of Poisson sampling when discrete particles are measured in small biological aliquots. A particle-based optical approach under development by ecotera health is presented as an emerging strategy intended to provide results for public health studies and routine clinical use.